Tags

Type your tag names separated by a space and hit enter

A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder.
Eur Neuropsychopharmacol 2008; 18(9):639-45EN

Abstract

We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46% women; mean age 42+/-14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of >or=18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n=14): 1 g/day of oral DHA; Group B (n=11): 2 g/day; and Group C (n=10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (>or=50% decrease in HAM-D-17 score) were 83% for Group A, 40% for Group B, and 0% for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p<0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p<0.05), EPA had little change (p>0.05), and n-6/n-3 decreased significantly (p<0.05). DHA may be effective for depression at lower doses.

Authors+Show Affiliations

Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States. dmischoulon@partners.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18539007

Citation

Mischoulon, David, et al. "A Double-blind Dose-finding Pilot Study of Docosahexaenoic Acid (DHA) for Major Depressive Disorder." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 18, no. 9, 2008, pp. 639-45.
Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008;18(9):639-45.
Mischoulon, D., Best-Popescu, C., Laposata, M., Merens, W., Murakami, J. L., Wu, S. L., ... Fava, M. (2008). A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 18(9), pp. 639-45. doi:10.1016/j.euroneuro.2008.04.011.
Mischoulon D, et al. A Double-blind Dose-finding Pilot Study of Docosahexaenoic Acid (DHA) for Major Depressive Disorder. Eur Neuropsychopharmacol. 2008;18(9):639-45. PubMed PMID: 18539007.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. AU - Mischoulon,David, AU - Best-Popescu,Catherine, AU - Laposata,Michael, AU - Merens,Wendelien, AU - Murakami,Jessica L, AU - Wu,Shirley L, AU - Papakostas,George I, AU - Dording,Christina M, AU - Sonawalla,Shamsah B, AU - Nierenberg,Andrew A, AU - Alpert,Jonathan E, AU - Fava,Maurizio, Y1 - 2008/06/06/ PY - 2007/09/27/received PY - 2008/04/07/revised PY - 2008/04/17/accepted PY - 2008/6/10/pubmed PY - 2008/12/19/medline PY - 2008/6/10/entrez SP - 639 EP - 45 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 18 IS - 9 N2 - We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA). Thirty-five depressed adult outpatients (46% women; mean age 42+/-14 years) with a 17-item Hamilton-Depression Scale (HAM-D-17) score of >or=18 were randomized into one of three double-blind dosing arms for 12 weeks. Group A (n=14): 1 g/day of oral DHA; Group B (n=11): 2 g/day; and Group C (n=10): 4 g/day. We measured HAM-D-17 scores, plasma DHA, eicosapentaenoic acid (EPA), and n-6/n-3 ratio. Completer response rates (>or=50% decrease in HAM-D-17 score) were 83% for Group A, 40% for Group B, and 0% for Group C; Groups A and B had significant decreases in HAM-D-17 scores (p<0.05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p<0.05), EPA had little change (p>0.05), and n-6/n-3 decreased significantly (p<0.05). DHA may be effective for depression at lower doses. SN - 0924-977X UR - https://www.unboundmedicine.com/medline/citation/18539007/A_double_blind_dose_finding_pilot_study_of_docosahexaenoic_acid__DHA__for_major_depressive_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(08)00108-9 DB - PRIME DP - Unbound Medicine ER -